Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics (DMAC)
:DMAC
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: -36.23%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the preeclampsia and stroke programs, particularly with the expansion of clinical sites and positive safety reviews. However, challenges such as delayed enrollment in the stroke program and increased R&D expenses were noted. Despite these challenges, the overall sentiment leans towards optimism due to the advancements and financial stability.Company Guidance
During the DiaMedica Therapeutics Full Year 2024 Conference Call, significant guidance was provided regarding the company's clinical development programs and financial outlook. For the preeclampsia program, the company highlighted the progress in their Phase 2 trial, including ethics approval and initial dosing of DM199, emphasizing its safety profile and potential to lower blood pressure without crossing the placental barrier. They anticipate results from Part 1A of the trial in the second quarter of 2025. In their stroke program, 30 clinical sites have been activated with a protocol that includes broader patient criteria and improvements in drug storage logistics, aiming for an interim analysis in the first half of 2026. Financially, DiaMedica reported a total combined cash and investments of $44.1 million as of December 31, 2024, with a net cash used in operating activities of $22.1 million for the year. The company projects a financial runway into the third quarter of 2026.Progress in Preeclampsia Program
DiaMedica obtained ethics approval and began dosing preeclamptic mothers in their DM199 study, marking the first study of DM199 in a pregnancy-related condition. This highlights DM199's potential as a treatment for preeclampsia, a condition with no FDA-approved treatments.
Expansion of Stroke Program
Activated 30 clinical sites for the stroke study, with plans to expand globally. The study protocol has been updated to include more patient populations, potentially increasing enrollment.
Strong Financial Position
DiaMedica reported a total combined cash and investments of $44.1 million, providing a financial runway into Q3 of 2026.
Positive Safety Review
The Data Safety Monitoring Board completed a comprehensive safety review, finding no significant safety concerns, allowing the ReMEDy2 trial to continue without modification.
---
DMAC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DMAC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $5.99 | $5.21 | -13.02% |
| Nov 13, 2024 | $4.26 | $4.12 | -3.29% |
| Aug 07, 2024 | $3.25 | $3.35 | +3.08% |
| May 08, 2024 | $3.47 | $3.25 | -6.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Diamedica Therapeutics (DMAC) report earnings?
Diamedica Therapeutics (DMAC) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Diamedica Therapeutics (DMAC) earnings time?
Diamedica Therapeutics (DMAC) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DMAC EPS forecast?
DMAC EPS forecast for the fiscal quarter 2025 (Q1) is -0.18.
---